Semaglutide Shortage Update: New Compounding Rules Take Effect June 2026
The FDA has announced new compounding regulations for GLP-1 medications. Here is what patients and telehealth providers need to know about sourcing compounded semaglutide safely.
GoGLP1 earns a commission from qualifying provider enrollments via links on this page. This never affects our editorial rankings or reviews. Full disclosure.
The FDA’s revised guidance on compounding GLP-1 receptor agonists takes effect in June 2026, introducing stricter requirements for compounding pharmacies that produce semaglutide and tirzepatide formulations. Here is what patients need to know.
Background
Since 2023, the FDA has maintained semaglutide on its drug shortage list, allowing compounding pharmacies to produce customized versions of the medication under Section 503A of the Federal Food, Drug, and Cosmetic Act. As supply constraints ease, the agency is tightening oversight.
Key Changes
The new regulations include:
- Enhanced ingredient sourcing requirements: Compounding pharmacies must source active pharmaceutical ingredients (APIs) from FDA-registered facilities with current Good Manufacturing Practice (cGMP) certification
- Updated sterility testing protocols: All injectable GLP-1 compounds must undergo USP <71> sterility testing before release, with results documented and retained for inspection
- Stricter beyond-use dating: Beyond-use dates for compounded semaglutide must reflect stability data specific to the formulation, not generic defaults
- Mandatory adverse event reporting: Compounding facilities must report serious adverse events to the FDA’s MedWatch system within 15 calendar days
What This Means for Patients
If you are currently receiving compounded semaglutide or tirzepatide through a telehealth provider, these changes are designed to protect you. The stricter requirements mean:
- Higher confidence in product quality: Only pharmacies meeting the new standards can continue compounding GLP-1 medications
- Clearer labeling: Compounded products must include specific beyond-use dates and storage instructions
- Better adverse event tracking: Any safety issues will be reported to the FDA more quickly
How to Verify Your Compounding Pharmacy
Patients should verify that their compounding pharmacy:
- Holds a valid state pharmacy license
- Is registered with the FDA (for 503B outsourcing facilities)
- Follows USP <795> (non-sterile) or <797> (sterile) compounding standards
- Sources APIs from FDA-registered suppliers
- Provides a certificate of analysis for each batch
Our compounding pharmacy verification guide provides a detailed checklist for patients evaluating compounding sources.
Looking Ahead
As branded GLP-1 supply stabilizes and generic options enter the market, the role of compounding pharmacies in GLP-1 therapy will continue to evolve. We expect to see further regulatory refinement throughout 2026 as the FDA balances patient access with safety oversight.
James Patrick Kelly, RPh, contributed to this report. Clinically reviewed by Dr. Priya Sharma, MD.
Ready to start?
Our top-rated GLP-1 providers, reviewed and tested. We may earn a commission — see our editorial policy.
Affiliate disclosure: GoGLP1 earns a commission from qualifying enrollments. This never affects our rankings or reviews. Reviewed 2026.